- Eiger BioPharmaceuticals Inc EIGR announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine.
- The data exhibited that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger’s investigational agent, peginterferon lambda, resulted in significantly decreased clinical events.
- The primary endpoint was a composite endpoint of COVID-19-related hospitalization or emergency room visits greater than six hours.
- Secondary endpoints included SARS-CoV-2 viral clearance, all-cause hospitalization, mortality due to COVID-19, days in the hospital and on a ventilator, and adverse events.
- In the study, 931 patients received peginterferon lambda, and 1,018 received a placebo.
- The publication detailed results, highlighting a 51% reduction in the risk of hospitalization or emergency room visits (primary endpoint) with peginterferon lambda.
- Lambda reduced the risk of hospitalization by 42% and COVID-19-related death by 50%
- Related: Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment.
- The risk of COVID-19 hospitalization or all-cause death was reduced by 47% in participants receiving peginterferon lambda.
- In patients receiving treatment within three days of symptom onset, greater treatment effects were observed in the peginterferon lambda group, including a 65% reduction of COVID-19-related hospitalization, 81% risk reduction in all-cause death, and 89% risk reduction among unvaccinated patients.
- Price Action: EIGR shares are up 39.9% at $2.85 on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
